- Home
- TNYA vs EPIX Comparison
TNYA vs EPIX Comparison
Compare TNYA & EPIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNYA
- EPIX
- Stock Information
- Founded
- TNYA 2016
- EPIX 2009
- Country
- TNYA United States
- EPIX Canada
- Employees
- TNYA N/A
- EPIX N/A
- Industry
- TNYA Medicinal Chemicals and Botanical Products
- EPIX Biotechnology: Pharmaceutical Preparations
- Sector
- TNYA Health Care
- EPIX Health Care
- Exchange
- TNYA Nasdaq
- EPIX Nasdaq
- Market Cap
- TNYA 138.1M
- EPIX 73.5M
- IPO Year
- TNYA 2021
- EPIX N/A
- Fundamental
- Price
- TNYA $1.67
- EPIX $1.60
- Analyst Decision
- TNYA Strong Buy
- EPIX Hold
- Analyst Count
- TNYA 4
- EPIX 3
- Target Price
- TNYA $17.33
- EPIX $2.00
- AVG Volume (30 Days)
- TNYA 7.5M
- EPIX 315.6K
- Earning Date
- TNYA 11-06-2024
- EPIX 12-17-2024
- Dividend Yield
- TNYA N/A
- EPIX N/A
- EPS Growth
- TNYA N/A
- EPIX N/A
- EPS
- TNYA N/A
- EPIX N/A
- Revenue
- TNYA N/A
- EPIX N/A
- Revenue This Year
- TNYA N/A
- EPIX N/A
- Revenue Next Year
- TNYA N/A
- EPIX N/A
- P/E Ratio
- TNYA N/A
- EPIX N/A
- Revenue Growth
- TNYA N/A
- EPIX N/A
- 52 Week Low
- TNYA $0.99
- EPIX $1.40
- 52 Week High
- TNYA $7.01
- EPIX $11.67
- Technical
- Relative Strength Index (RSI)
- TNYA 37.59
- EPIX 23.81
- Support Level
- TNYA $0.99
- EPIX $1.57
- Resistance Level
- TNYA $3.69
- EPIX $1.74
- Average True Range (ATR)
- TNYA 0.40
- EPIX 0.06
- MACD
- TNYA -0.27
- EPIX 0.09
- Stochastic Oscillator
- TNYA 22.59
- EPIX 14.29
About TNYA Tenaya Therapeutics Inc.
Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration, and precision medicine.
About EPIX ESSA Pharma Inc.
ESSA Pharma Inc is a pharmaceutical company. The company is focused on the development of small molecule drugs for the treatment of castration-resistant prostate cancer. The company is developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival.